ArticleBritish journal of cancer2000
Prognostic value of genomic alterations in minimal residual cancer cells purified from the blood of breast cancer patients.
Article in British journal of cancer, 2000. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 45 citations in OpenAlex.
- cfDNA Sequencing: Technological Approaches and Bioinformatic Issues.Pharmaceuticals (Basel, Switzerland) · 2021Review
- Semaphorin 3F and Netrin-1: The Novel Function as a Regulator of Tumor Microenvironment.Frontiers in physiology · 2018Review
- [Blood-based Tumor Markers in Lung Cancer].Zhongguo fei ai za zhi = Chinese journal of lung cancer · 2015Review
- NY-ESO-1 antibody as a novel tumour marker of gastric cancer.British journal of cancer · 2013Article
- Netrin-1 promotes glioblastoma cell invasiveness and angiogenesis by multiple pathways including activation of RhoA, cathepsin B, and cAMP-response element-binding protein.The Journal of biological chemistry · 2013Article
- Evaluation of a multi-marker immunomagnetic enrichment assay for the quantification of circulating melanoma cells.Journal of translational medicine · 2012Article
- Deleted in colorectal carcinoma suppresses metastasis in p53-deficient mammary tumours.Nature · 2012Article
- Epithelial-to-mesenchymal transitions and circulating tumor cells.Journal of mammary gland biology and neoplasia · 2010Review
- The measurement and therapeutic implications of circulating tumour cells in breast cancer.British journal of cancer · 2006Review
- The role of c-erbB-2/HER2/neu in breast cancer progression and metastasis.Journal of mammary gland biology and neoplasia · 2001Review
Corrections and comments
- Erratum issued
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The prognostic value of disseminated tumour cells derived from 353 breast cancer patients was evaluated. Disseminated tumour cells were purified from blood using a newly established method and nucleic acids were subsequently isolated. We investigated genomic imbalances (GI) such as mutation, amplification and loss of heterozygosity of 13 tumour suppressor genes and 2 proto-oncogenes using DNA from isolated minimal residual cancer cells. Significant correlations were found between genomic alterations of the DCC - and c-erbB-2 genes in disseminated breast cancer cells and actuarial relapse-free survival. Furthermore, increasing numbers of genomic imbalances measured in disseminated tumour cells were significantly associated with worse prognosis of recurrent disease. Logistic regression and Cox multivariate analysis led to the identification of genomic imbalances as an independent prognostic factor. Determination of disseminated tumour cells by genotyping of oncogenes and tumour suppressor genes seems not only to be a useful adjunct in follow up of carcinoma patients but provides also valuable additional individualized prognostic and predictive information in breast cancer patients beyond the TNM system.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.